Screener
Corcept Therapeutics CORT Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accrued research and development expenses | 21,628 | 33,954 |
| Accrued and other liabilities | 115,347 | 90,603 |
| Short-term operating lease liability | 1,917 | 1,084 |
| Total current liabilities | 153,802 | 166,085 |
| Long-term operating lease liability | 7,504 | 5,023 |
| Long-term accrued government rebates | 6,132 | 2,562 |
| Long-term accrued income taxes | 15,488 | 15,176 |
| Total liabilities | 182,926 | 188,846 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's total current liabilities?
- Corcept Therapeutics (CORT) reported total current liabilities of $153.8M in Q2 2026.
- How has Corcept Therapeutics's total current liabilities changed year-over-year?
- Corcept Therapeutics's total current liabilities increased by 6.3% year-over-year, from $144.66M to $153.8M.
- What is the long-term trend for Corcept Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Corcept Therapeutics's total current liabilities has grown at a 28.5% compound annual growth rate (CAGR), from $47.49M to $166.09M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Corcept Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude